<?xml version="1.0" encoding="UTF-8"?>
<p id="Par23">Cook et al., 2017 reported that however, the proportion of those reporting adverse event relating to drug consumption for NTX receiving participants are greater compared to placebo (70% vs. 28%), these differences were not significant statistically (
 <italic>p</italic> = 0.15 by Fisher exact test) [
 <xref ref-type="bibr" rid="CR44">44</xref>]. According to Cook et al., 2017 the most common side effects for NTX users were: insomnia (30%), nervousness/anxiety (30%), and nausea (10%). Also, Springer et al., 2017 reported no statistical differences in adverse events between the XR-NTX or placebo groups [
 <xref ref-type="bibr" rid="CR50">50</xref>]. In another study by Edelman et al. 2019, 51% of participants experienced one or more adverse events with mild to moderate severity and 18% had a serious adverse event. The reported adverse events were different and include neurological, muscular, gastrointestinal, psychiatric, slips and falls, legal, family and social problems and other problems associated with using drug/alcohol [
 <xref ref-type="bibr" rid="CR45">45</xref>]. Among 51 patient participated in Korthuis et al., 2017 study, 40 of them experienced 29 adverse events but most of them (62%) were not associated with the study treatment [
 <xref ref-type="bibr" rid="CR47">47</xref>].
</p>
